Sign in
Taking peoplePhase 4

L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction

Key facts

Who runs it
Beni-Suef University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
133 people, planned
Started
8 Jun 2026
Expected to end
Dec 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • L-Citrulline
  • Tadalafil
  • L-Citrulline Placebo
  • Tadalafil Placebo
Record updated
12 June 2026

Who can take part

Age
30 years to 70 years
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (20)Hide the full registry criteria

Who can take part

  • Male patients aged 30 to 70 years
  • Erectile dysfunction for at least 3 months
  • Mild to moderate erectile dysfunction, defined by International Index of Erectile Function-Erectile Function domain score from 11 to 25
  • Stable sexual relationship during the study period
  • Willingness to attempt sexual activity during the study period
  • Ability to complete study questionnaires and attend follow-up visits
  • Written informed consent

Who cannot take part

  • Major neurogenic erectile dysfunction, spinal cord injury, or previous radical pelvic surgery causing severe erectile dysfunction
  • Use of phosphodiesterase type 5 inhibitors, intracavernosal injection therapy, vacuum device therapy, testosterone therapy, L-arginine, L-citrulline, or erectile dysfunction nutraceuticals during the washout period before randomization
  • Participation in another clinical trial during the previous 3 months
  • Contraindication or hypersensitivity to tadalafil or L-citrulline
  • Unstable cardiovascular disease, unstable angina, recent myocardial infarction or stroke, uncontrolled hypertension, or high-risk arrhythmia
  • Severe hepatic impairment
  • Severe renal impairment
  • Hyperprolactinemia or uncontrolled endocrine disorder
  • Significant Peyronie's disease preventing intercourse
  • Active major psychiatric illness impairing reliable assessment
  • Severe erectile dysfunction, defined by International Index of Erectile Function-Erectile Function domain score of 10 or less
  • Current nitrate or nicorandil use
  • Untreated hypogonadism requiring hormonal treatment

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Erectile dysfunction

This trial is currently available in Egypt.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Erectile dysfunction is a common male sexual health problem that may affect quality of life and sexual relationships. Tadalafil 5 mg once daily is an established oral treatment for erectile dysfunction. L-citrulline is an oral nitric oxide pathway supplement that may improve erectile function by increasing L-arginine availability.

Read full original descriptionShow less

This randomized trial will compare three oral treatment regimens in men with mild to moderate erectile dysfunction: L-citrulline 1500 mg/day, tadalafil 5 mg/day, and the combination of L-citrulline 1500 mg/day plus tadalafil 5 mg/day. Participants will receive treatment for 12 weeks and will be followed at baseline, week 4, week 8, and week 12.

The primary outcome will be the change in the International Index of Erectile Function-Erectile Function domain score from baseline to 12 weeks. Secondary outcomes will include changes in IIEF-5/SHIM score, Erection Hardness Score, SEP diary outcomes, treatment adherence, adverse events, and treatment discontinuation.

The 3 groups in the trial

  • L-CitrullineTreatment being tested

    Participants assigned to this arm will receive oral L-citrulline 1500 mg/day for 12 weeks. In the double-dummy design, participants will receive active L-citrulline plus tadalafil placebo.

    Treatment: L-Citrulline and Tadalafil Placebo

  • TadalafilExisting treatment, for comparison

    Participants assigned to this arm will receive oral tadalafil 5 mg once daily for 12 weeks. In the double-dummy design, participants will receive active tadalafil plus L-citrulline placebo.

    Treatment: Tadalafil and L-Citrulline Placebo

  • L-Citrulline Plus TadalafilTreatment being tested

    Participants assigned to this arm will receive combination oral therapy with L-citrulline 1500 mg/day plus tadalafil 5 mg once daily for 12 weeks.

    Treatment: L-Citrulline and Tadalafil

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
L-Citrulline Versus Tadalafil Versus Combination Therapy in Mild to Moderate Erectile Dysfunction: A Prospective Randomized Trial
Criteria questions
Built from NCT07642505, who can take part
Record updated
12 June 2026